단가아민 재흡수 억제 활성을 보이는 (1S,3aR,9bS)-1-페닐-2,3,3a,4,5,9b-헥사하이드로-1H-벤조[e]인돌 유도체와 3,4-다이아릴피롤리딘-2-온 유도체
    52.
    发明公开
    단가아민 재흡수 억제 활성을 보이는 (1S,3aR,9bS)-1-페닐-2,3,3a,4,5,9b-헥사하이드로-1H-벤조[e]인돌 유도체와 3,4-다이아릴피롤리딘-2-온 유도체 有权
    (1S,3AR,9BS)-1-苯基-2,3,3a,4,5,9B-十六氢-1H-苯并[E]吲哚衍生物和具有抑制单胺反应的3,4-二氨基吡啶-2-酮衍生物

    公开(公告)号:KR1020130088988A

    公开(公告)日:2013-08-09

    申请号:KR1020120010286

    申请日:2012-02-01

    Abstract: PURPOSE: A novel compound is provided to suppress triple reuptake by blocking serotonin, norepinephrine, and dopamine. CONSTITUTION: A compound selected among (1S,3aR,9bS)-1-phenyl-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole derivatives and pharmaceutically acceptable salts thereof is denoted by chemical formula 1. The compound is selected among (1S,3aR,9bS)-9-chloro-1-phenyl-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole, (1S,3aR,9bS)-8-chloro-1-phenyl-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole, (1S,3aR,9bS)-7-chloro-1-phenyl-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole, (1S,3aR,9bS)-7,8-dichloro-1-phenyl-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole, and pharmaceutically acceptable salts thereof. A pharmaceutical composition for preventing and treating depression contains the compound as an active ingredient.

    Abstract translation: 目的:通过阻断5-羟色胺,去甲肾上腺素和多巴胺来提供新的化合物来抑制三重再摄取。 构成:选自(1S,3aR,9bS)-1-苯基-2,3,3a,4,5,9b-六氢-1H-苯并[e]吲哚衍生物及其药学上可接受的盐的化合物由化学式 该化合物选自(1S,3aR,9bS)-9-氯-1-苯基-2,3,3a,4,5,9b-六氢-1H-苯并[e]吲哚,(1S,3aR, 9bS)-8-氯-1-苯基-2,3,3a,4,5,9b-六氢-1H-苯并[e]吲哚,(1S,3aR,9bS)-7-氯-1-苯基-2 ,3,3a,4,5,9b-六氢-1H-苯并[e]吲哚,(1S,3aR,9bS)-7,8-二氯-1-苯基-2,3,3a,4,5,9b 六氢-1H-苯并[e]吲哚及其药学上可接受的盐。 用于预防和治疗抑郁症的药物组合物含有作为活性成分的化合物。

    칼슘 채널에 활성을 지닌 신규 피라조일 피페라진 화합물
    56.
    发明公开
    칼슘 채널에 활성을 지닌 신규 피라조일 피페라진 화합물 有权
    吡唑基哌嗪化合物作为钙通道拮抗剂

    公开(公告)号:KR1020120125098A

    公开(公告)日:2012-11-14

    申请号:KR1020110043180

    申请日:2011-05-06

    Abstract: PURPOSE: A pyrazolyl piperazine compound with a pharmaceutical activity to a calcium channel and a pharmaceutical composition containing the same are provided to be used as a pharmaceutical composition for preventing or treating diseases of brain diseases, heart diseases, cancer, and pain. CONSTITUTION: A pyrazolyl piperazine compound is denoted by chemical formula 1. The compound of chemical formula 1 is prepared by binding piperazine compounds of chemical formula 2 and chloride compounds of chemical formula 3 under the presence of a base at 20-30 Deg. C. The base includes an organic base such as an amine-based base and an inorganic base. The reaction solvent is dichloromethane, tetrahydrofurane(THF), dimethyl formamide(DMF), dimethyl aceteamide(DMAC), and dioxane. A pharmaceutical composition for preventing brain diseases, cancer, heart diseases, or pain contains the compound of chemical formula 1.

    Abstract translation: 目的:提供对钙通道具有药学活性的吡唑基哌嗪化合物和含有该通道的药物组合物作为预防或治疗脑疾病,心脏病,癌症和疼痛疾病的药物组合物。 构成:化学式1表示吡唑基哌嗪化合物。化学式1的化合物是通过在20-30度的碱存在下将化学式2的哌嗪化合物和化学式3的氯化合物结合而制备的。 C.碱包括有机碱如胺基和无机碱。 反应溶剂为二氯甲烷,四氢呋喃(THF),二甲基甲酰胺(DMF),二甲基乙酰胺(DMAC)和二恶烷。 用于预防脑疾病,癌症,心脏病或疼痛的药物组合物含有化学式1的化合物。

    T-형 칼슘 채널에 활성을 지닌 신규 다이페닐프로판노일 화합물
    59.
    发明公开
    T-형 칼슘 채널에 활성을 지닌 신규 다이페닐프로판노일 화합물 有权
    具有T型钙通道活性的新型二苯基丙烯酸酯化合物

    公开(公告)号:KR1020110119045A

    公开(公告)日:2011-11-02

    申请号:KR1020100038514

    申请日:2010-04-26

    CPC classification number: Y02P20/55

    Abstract: PURPOSE: A diphenylpropanoyl compound having T-type calcium channel activity is provided to ensure antagonism to a T-type calcium channel and to be used as a therapeutic agent and anticancer agent. CONSTITUTION: A diphenylpropanoyl is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating hypertension, angina, chronic pain, neurogenic pain or cancer contains a compound of chemical formula 1 as an active ingredient. A method for preparing the compound of chemical formula 1 comprises a step of binding a compound of chemical formula 2 with a compound of chemical formula 3.

    Abstract translation: 目的:提供具有T型钙通道活性的二苯基丙酰基化合物,以确保对T型钙通道的拮抗作用,并用作治疗剂和抗癌剂。 构成:二苯基丙酰基由化学式1表示。用于预防和治疗高血压,心绞痛,慢性疼痛,神经源性疼痛或癌症的药物组合物含有化学式1化合物作为活性成分。 制备化学式1的化合物的方法包括将化学式2的化合物与化学式3的化合物结合的步骤。

Patent Agency Ranking